Table 3 Model-recommended treatment strategies for achieving EPHP and EOT (after the achievement of EPHP) for low adult burden of infection. Results for low-transmission settings are generated using the ICL model
From: Determining the optimal strategies to achieve elimination of transmission for Schistosoma mansoni
Prevalence in SAC prior to treatment | Model | Model-recommended treatment strategy for achieving EPHP [13] | Model-recommended treatment strategy for achieving EOT after the achievement of EPHP |
|---|---|---|---|
Low (< 10%) | ICL | 75% SAC for 2–3 years | 75% SAC and 30% adults for 5–6 years |
Moderate (10–50%) | ICL | 75% SAC for 4 years | 75% SAC and 40% adults for 8–9 years |
SCHISTOX | 75% SAC for 5 years | 75% SAC and 40% adults for 6–7 years | |
High (≥ 50%) | ICL | 75% SAC for 4–10 years (baseline prevalence below 67% SAC + 56% adults) 90% SAC and 45% adults for 10 years (baseline prevalence: 71% SAC + 60% adults) | 75% SAC and 50% adults for 8–10 years (baseline prevalence below 67% SAC + 56% adults) 75% SAC and 50% adults for 5 years (baseline prevalence: 71% SAC + 60% adults) |
SCHISTOX | 75% SAC for 5–10 years (baseline prevalence below 76% SAC + 42% adults) 90% SAC and 45% adults for 8 years (baseline prevalence: 79% SAC + 49% adults) | 75% SAC and 50% adults for 7–8 years (baseline prevalence below 76% SAC + 42% adults) 75% SAC and 50% adults for 5 years (baseline prevalence: 79% SAC + 49% adults) |